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A painful neuropathy is frequently observed in people living with human immunodeﬁciency virus type 1 (HIV-1). The HIV coat
protein, glycoprotein 120 (gp120), implicated in the pathogenesis of neurological disorders associated with HIV, is capable of ini-
tiating neurotoxic cascades via an interaction with the CXCR4 and/or CCR5 chemokine receptors, which may underlie the path-
ogenesis of HIV-associated peripheral neuropathic pain. In order to elucidate the mechanisms underlying HIV-induced painful
peripheral neuropathy, we have characterised pathological events in the peripheral and central nervous system following application
of HIV-1 gp120 to the rat sciatic nerve. Perineural HIV-1 gp120 treatment induced a persistent mechanical hypersensitivity (44%
decrease from baseline), but no alterations in sensitivity to thermal or cold stimuli, and thigmotactic (anxiety-like) behaviour in
the open ﬁeld. The mechanical hypersensitivity was sensitive to systemic treatment with gabapentin, morphine and the cannabinoid
WIN 55,212-2, but not with amitriptyline. Immunohistochemical studies reveal: decreased intraepidermal nerve ﬁbre density, mac-
rophage inﬁltration into the peripheral nerve at the site of perineural HIV-1 gp120; changes in sensory neuron phenotype including
expression of activating transcription factor 3 (ATF3) in 27% of cells, caspase-3 in 25% of cells, neuropeptide Y (NPY) in 12% of
cells and galanin in 13% of cells and a spinal gliosis. These novel ﬁndings suggest that this model is not only useful for the elucidation
of mechanisms underlying HIV-1-related peripheral neuropathy but may prove useful for preclinical assessment of drugs for the
treatment of HIV-1 related peripheral neuropathic pain.
 2007 International Association for the Study of Pain. Published by Elsevier B.V.
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Distal symmetrical polyneuropathy (DSP) aﬄicts 15–
50% of people living with HIV-1 (Marshall et al., 2005;
Verma et al., 2005), 50–60% of whom have measurable
sensory abnormalities (Martin et al., 2003) and on-going,0304-3959 2007 International Association for the Study of Pain. Published
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5109.
E-mail address: a.rice@imperial.ac.uk (A.S.C. Rice).paroxysmal or stimulus evoked pain (Dalakas and Pezes-
hkpour, 1988; Martin et al., 1999). There are two pre-
dominant (and clinically similar) settings in which
painful DSP may occur in HIV-disease. Firstly, a dis-
ease-related DSP associated with advanced disease and
secondly a drug-induced DSP associated with the use
of nucleoside reverse transcriptase inhibitors as part of
an anti-retroviral therapy (Martin et al., 2003; Marshall
et al., 2005). This study is solely concerned with the for-
mer scenario, which we will refer to as HIV-DSP. Theby Elsevier B.V. Open access under CC BY license.
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and nerve conduction studies suggest axonal degenera-
tion of both large and small diameter myelinated and
unmyelinated axons and measurement of thermal thresh-
olds reveals a high prevalence of thermal hypoesthsesia
(and by implication a deﬁcit in small ﬁbre function)
(Martin et al., 2003). Direct infection of the nervous sys-
tem by HIV is thought to be unlikely (Michaels et al.,
1988; Lipton, 1998) instead, HIV-1 appears to interact
indirectly with neurons via binding of the external enve-
lope protein, gp120, to the chemokine receptors CXCR4
and/or CCR5. In line with this, HIV-1 gp120 causes
apoptosis in various central nervous system (CNS) neu-
ronal populations in vitro (Lipton, 1991; Bennett et al.,
1995) and in vivo (Bagetta et al., 1996; Corasaniti et al.,
2001) and results in marked pain-like behaviour when
injected into the spinal intrathecal space in rats (Milligan
et al., 2000) or mice (Minami et al., 2003). In the periph-
eral nervous system, HIV-1 gp120 can inﬂuence the
activity (Oh et al., 2001) and survival (Keswani et al.,
2003) of sensory neurons and has recently been shown
to interact directly with axons in vitro leading to toxicity
(Melli et al., 2006). Accordingly, peripheral administra-
tion of gp120 is associated with the development of
pain-like behaviour in rats (Herzberg and Sagen, 2001)
suggesting the possibility that HIV-1 gp120 interactions
with the peripheral nerve may be a causative factor in
the generation of peripheral neuropathic pain in humans.
In an eﬀort to elucidate HIV-associated neuropathic pain
pathophysiology we have pharmacologically and mecha-
nistically characterised the eﬀects of perineural delivery
of HIV-1 gp120 in rats and associated pain and co-mor-
bidity behaviour. To draw parallels between this model
and data from human studies, we have pharmacologi-
cally validated the associated behavioural sensitivity
with drugs known to possess analgesic eﬃcacy in other
rodent models of neuropathic pain and from randomised
controlled trials conducted in humans, including ami-
triptyline, gabapentin, morphine and the cannabinoid
agonist WIN-55,212-2. Finally, we have assessed the
eﬀects of perineural HIV-1 gp120 on: peripheral nerve
morphology, innervation of sensory target tissues, sen-
sory neuronal phenotype, and the activity of non-neuro-
nal, particularly immune, cells in the PNS and CNS.
2. Materials and methods
2.1. Animals and surgical methods
All experiments conformed to the British Home Oﬃce Reg-
ulations and IASP guidelines (Zimmermann, 1983). Male Wis-
tar rats weighing 200–250 g were used for all experiments (B &
K, Hull, UK) and were housed in a temperature-controlled
environment, maintained on a 14:10 h light–dark cycle (exper-
iments were performed during the light phase) and provided
with feed and water ad libitum. Under 1–2% isoﬂurane anaes-thesia (Abbott, UK) in 1% O2 and 1% N2O, and aseptic surgi-
cal conditions, the left sciatic nerve was exposed in the
popliteal fossa without damaging the perineurium. In six rats
a partial sciatic nerve injury (PSNI) (Seltzer et al., 1990) was
performed in which 1/3–1/2 of the sciatic nerve was tightly
ligated using 7.0 suture thread (Ethicon, Edinburgh, UK).
The wound was then closed with 4.0 sutures and animals
allowed to recover. For perineural HIV-1 gp120 delivery, the
nerve was initially exposed to the HIV-1 gp120 protein or vehi-
cle control by placing a 5 mm · 2 mm piece of gel foam (Ethi-
con) soaked in saline containing 0.1% rat serum albumin
(RSA) (Sigma, Poole, UK) and 200 ng HIV-1 gp120-MN
(>95% pure; Immunodiagnostics, Bedford, MA) or saline con-
taining just RSA in direct contact with the nerve to form a
pool of protein solution around the nerve and left in place
for 30 min. Following this, oxidised regenerated cellulose (Sur-
gicell, Ethicon), previously soaked until saturation in the same
200 ll of saline containing 200 ng gp120-MN or RSA, was
wrapped loosely around the sciatic nerve 2–3 mm proximal
to the trifurcation so as not to cause any nerve constriction
and left in situ (modiﬁed from (Herzberg and Sagen, 2001)).
The nerve was gently manipulated back into place and the
muscle and skin incisions closed with 4/0 silk sutures (Ethi-
con). In both surgical models 0.05 ml of 0.25% Bupivacaine
(STR, UK) was administered to the wound s.c. and 5 mg/kg
carprofen administered i.p. 3–4 h post-operatively.
2.2. Behavioural reﬂex testing
The threshold for hind paw withdrawal in response to
graded mechanical stimulation was measured in conscious
animals using two types of device. Firstly, graded von Frey
nylon ﬁlaments (Alan Ainsworth, UCL, London), which were
used to deliver a calibrated indentation pressure against the
hairless skin of the hind paws and for which the threshold
response was deﬁned by the nominal bending force of the ﬁl-
ament that evoked foot withdrawal at least three times in
every ﬁve applications when delivered at a rate of 1 Hz (Cha-
plan et al., 1994). Secondly, an electronic von Frey device
(Ahmad and Rice, 1999) of 0.5 mm2 probe tip area (Somedic
Sales AB, Sweden) applied manually at a rate of 8–15 g/s to
the mid-plantar surface of the hind paw with the withdrawal
threshold (g) deﬁned as the average force that evoked an
active limb withdrawal response over ﬁve applications. As
the electronic von Frey device is less well characterised, we
chose to use calibrated von Frey hairs as a validation of its
sensitivity to detect threshold changes. The time for hind
paw withdrawal in response to a quantiﬁed noxious heat
stimulus was assessed using the Plantar test (Ugo Basile,
Italy) (Hargreaves et al., 1988). The thermal stimulus (set at
an infrared intensity that produced standard latency of
approx. 10 s) was applied to the mid-plantar surface of the
hind paw and the latency (seconds) to withdrawal recorded
over three applications. The presence of a behavioural corre-
late of cold allodynia was assessed using the acetone drop
application technique (Bridges et al., 2001). A single drop
of acetone was applied via a 1 ml syringe to the mid-plantar
surface of each hind paw and the outcome deﬁned as the per-
centage of applications which evoked an active limb with-
drawal from a total of ﬁve applications.
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per group) over the course of a week prior to surgery. Behav-
ioural reﬂex tests were then carried out in a blinded and random-
ised manner following surgery to identify the development of
any reﬂex sensitivity in treated animals. The threshold value at
each time point tested was calculated as the mean ± SEM.
2.3. Open ﬁeld activity
At days 7 and 14 post surgery, rats (n = 8 per group) were
placed into a 1 m · 1 m arena illuminated to 4 lux with a
deﬁned inner zone of 40 cm · 40 cm. Locomotion of the rats
within the arena was tracked over a 15 min period recorded
using a Sanyo VCB 3372 high-resolution monochrome camera
(Tracksys, Notts, UK) and stored and analysed with Ethovi-
sion software v.3 (Tracksys). The total distance moved, time
spent in the inner zone and the number of entries into the inner
zone were calculated and displayed as the mean ± SEM. For
HIV-1 gp120 treated animals, only those with mechanical
hypersensitivity (a change of at least 30% from baseline) as
demonstrated using the electronic von Frey device were
included (100% inclusion rate).
2.4. Pharmacological manipulation
For all experiments, animals were block randomised to
treatment groups and the experimenter blinded to drug
treatments received. Behavioural responses to punctuate
mechanical stimuli were measured as described previously
using an electronic von Frey device. Baseline measurements
were obtained at least twice prior to surgery and post surgi-
cal values determined at days 11 and 14 post surgery. Only
animals that developed mechanical hypersensitivity of at
least 30% change were used for pharmacological experiments
(drop out rate of 10% with resulting n = 8 per group). To
test the eﬀect of chronic treatment with known analgesics,
we chose doses known to be eﬀective in rats limiting the
need for dose–response studies. Animals were administered
the drug or vehicle twice daily (8am and 6pm) on post sur-
gery days 15–18, and behavioural tests performed once each
day 1–2 h following the ﬁrst injection. The following drugs
were tested: morphine sulphate (Sigma; 2.5 mg/kg in 0.5 ml
saline i.p. b.d.); gabapentin (Pﬁzer Ltd 30 mg/kg in 0.5 ml
saline i.p. b.d.); the mixed CB1/CB2 cannabinoid receptor
agonist WIN 55,212-2 [(mesylate (R)-(+)-(2,3-dihydro-5-
methyl-3-(4-morpholinylmethyl)pyrrolo(1,2,3-de)-1, 4-benzox-
azin-6-yl)-1-naphthalenylmethanone) (Sigma) 2.5 mg/kg in
0.75 ml saline with 40% dimethylsulphoxide (DMSO) i.p.
b.d.]; and amitriptyline (Sigma 10 mg/kg in 0.5 ml saline
i.p. b.d.) (Hasnie et al., 2007).
2.5. Morphological investigations
Nerve morphology was examined in animals after sciatic
nerve exposure to HIV-1 gp120 (n = 8) or RSA (n = 6). At 7
(n = 7) and 14 (n = 7) days post surgery, 4 cm lengths of sciatic
nerve were removed from the experimental site. Under a dis-
secting microscope, a length of nerve that included the wrap
site, as determined by the localised discolouration of nerve
associated with resorbing oxidised cellulose, was removed,attached to a card in order prevent shrinkage during process-
ing, and immersion ﬁxed in 3% glutaraldehyde in 0.1 M phos-
phate buﬀer, pH 7.4. Specimens were subsequently washed,
postﬁxed in phosphate buﬀered OsO4 and processed through
to embedding in TAAB medium embedding resin (TAAB Lab-
oratories Equipment Ltd, Aldermaston, UK) for transverse
sectioning. Each nerve was divided in order to examine the
centre of the site of gp120 or RSA application, and sites within
1 cm proximal and distal to this point. Transverse 1 lm sec-
tions were subsequently stained with toluidine blue and
assessed under oil immersion using a Zeiss Axioplan2 light
microscope. The assessor was blinded to the treatment group
for analysis. From the same blocks assessed at LM, ultrathin
sections were saturated with uranyl acetate and lead citrate,
and viewed on the Hitachi H7600 electron microscope. For
each experimental group, six scattered ﬁelds of nerve were cho-
sen at random and photographed for the assessment of mor-
phology by a blinded observer.
2.6. Immunohistochemistry
Rats were deeply anaesthetised with pentobarbitone and
transcardially perfused with heparinised saline followed by
4% paraformaldehyde (Sigma) in 0.1 M PB (Sigma). The lum-
bar spinal cord, the treated sciatic nerve, the L4 and L5 DRGs
and the appropriate glabrous skin, excised bilaterally from the
wide part of the plantar hind paws (i.e., within the dermatomes
for sciatic nerve innervation), were removed. All tissue was
postﬁxed with the same ﬁxative for 4 h and transferred to
15% sucrose in 0.1 M PB for 2 h and left overnight in 30%
sucrose in 0.1 M PB. It was then embedded in optimum cryo-
stat temperature (OCT) mounting medium (VWR, Poole, UK)
and frozen over liquid nitrogen. Cryostat sections of DRG
(12 lm), L5 spinal cord (transverse, 20 lm), sciatic nerve (lon-
gitudinal, 15 lm) and hind paw skin (transverse, 15 lm) were
thaw-mounted on glass slides pre-coated with poly-L-lysine
(VWR).
For all ﬂuorescence immunohistochemistry, sections were
pre-incubated in buﬀer (0.1 M phosphate buﬀered saline
(PBS), pH 7.4, containing 0.2% Triton X-100) containing
10% normal donkey serum for 1 h at room temperature and
incubated with primary antibodies diluted in buﬀer containing
4% donkey serum overnight.
Antisera were used at the following concentrations; rabbit
anti-ATF3 (1:400; Santa Cruz Biotechnology, Santa Cruz,
CA), mouse anti p-c-Jun (1:500; Santa Cruz), rabbit anti-cal-
citonin gene related peptide (CGRP) (1:4000; Chemicon,
Hampshire, UK); rabbit anti-NPY (1:1000, Peninsula Labo-
ratories Inc, Belmont, CA); rabbit anti-galanin (1:2000; Pen-
insula, Cambridgeshire, UK); rabbit anti-growth associated
protein-43 (GAP-43) (1:1000; Chemicon,); rabbit anti-
cleaved caspase-3 (1:250; New England Biolabs, Hitchin,
UK); rabbit anti-transient receptor potential vanilloid 1
(TRPV1) (1:5000; Abcam Plc, Cambridge, UK) mouse
monoclonal anti-neuroﬁlament 200 kDa (NF200) (1:2000;
clone N52; Sigma); mouse anti-rat CD68 (ED1) (1:2500;
Serotec, Oxford, UK); rabbit anti-glial ﬁbrillary acidic pro-
tein (GFAP) (1:1000; Chemicon); rabbit anti-PGP 9.5
(1:1000; Ultraclone, Isle of White, UK); mouse anti-rat
OX-42 (1:800; Serotec). Sections were then washed in buﬀer
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linked to either isothiocyanate (Cy3) (donkey anti-mouse-
Cy3 1:300; Jackson ImmunoResearch Laboratories, West-
grove, PA) or ﬂuorescein isothiocyanate (FITC) (donkey
anti-rabbit-FITC 1:300; Jackson ImmunoResearch) for 2 h
at room temperature. Three ﬁnal washes in 0.1 M PBS were
conducted before cover-slipping with Vecta-Shield (Vector
Laboratories, Peterborough, UK) for analysis. Control sec-
tions were processed as above omitting the primary antisera.
For biotinylated labelling of microglia, sections were pre-
incubated with 0.3% H202 for 15 min, washed in PBS and incu-
bated with mouse anti-OX42 overnight. Sections were then
washed in PBS and incubated with biotinylated horse anti-
mouse antibody (1:400; Jackson ImmunoResearch) for
90 min. After a further wash in PBS, sections were incubated
with the avidin–biotin complex (Vector Labs) for 2 h, washed
as above, and the reaction developed with 3,3,-diaminobenzi-
dine (DAB; Vector Labs). Sections were then dehydrated in
increasing concentrations of alcohol (50–100%), cleared with
xylene and cover-slipped with DePex mounting medium
(VWR).
2.7. Image analysis and quantiﬁcation
All analysis was performed by an observer who was una-
ware of the experimental group of the tissue being examined.
Fluorescent images were visualised using a Leica (Leica, Mil-
ton Keynes, UK) ﬂuorescence microscope, equipped with the
appropriate ﬁlter blocks and captured at consistent exposure
times using a Hamamatsu CCD camera and analysed using
Leica QWin v.3.0 software (Leica). For DRG, analysis was
performed at 20· or 40· magniﬁcation on 6–8 randomly
selected 12 lm sections of DRG (separation of 180 lm) from
each of four to six animals per group (ipsilateral to HIV-1
gp120, contralateral to HIV-1 gp120 and ipsilateral to RSA),
only neurons with clear nuclei were counted. In each case,
the analysis was performed in an automated manner using
constant detection threshold levels determined from positive
control tissue (the DRG of rats 7 days following PSNL sur-
gery). The total number of neurons per section was determined
by counting both NF-200 labelled and non-labelled neuronal
cell bodies and number of DRG neurons expressing immuno-
reactivity (IR) for ATF3, p-c-Jun, CGRP, NPY, galanin
TRPV1, caspase-3 or GAP-43 reported as a percentage of total
number of neurons/section. In some cases, the proportion of
co-localised cells was also calculated. To quantify alterations
in satellite cell morphology within the DRG, the, number of
neuronal cell bodies associated with GFAP-IR was counted
and expressed as a percentage of total DRG neurons per sec-
tion. To quantify the activated or inﬁltrating macrophages in
DRG, regions of the DRG containing only sensory neuronal
cell bodies (excluding peripheral nerve) were analysed in a
deﬁned area (450 lm · 450 lm) within which the number of
CD68-IR cellular proﬁles was counted and expressed as the
total number of CD68-IR cellular proﬁles per unit area. For
the assessment of CD68-IR in the sciatic nerve, six sections
from each of six animals per group were captured in three
places; at the site of HIV-1 gp120 or RSA application, 1 cm
distal to or 1 cm proximal to application and analysis per-
formed in an area encompassing only nerve and not perineu-rium or remnants of oxidised cellulose. To quantify CD68-
IR in the sciatic nerve, the number of CD68-IR cellular proﬁles
was measured and expressed as total number of CD68-IR cel-
lular proﬁles per unit area (450 lm · 250 lm). To quantify epi-
dermal nerve ﬁbre linear density (McArthur et al., 1998), PGP
9.5-immunoreactive nerves were counted in the epidermis of
four footpad sections from each of four animals per group at
a magniﬁcation of 20· using previously described methods
(Hsieh et al., 2000; Lin et al., 2001; Keswani et al., 2006). Each
individual nerve with branching points inside the epidermis
was counted as one. For epidermal nerves with branching
points in the dermis, each individual nerve was counted sepa-
rately. The total length of the epidermis along the upper mar-
gin of the stratum corneum in each footpad was measured and
epidermal nerve density was expressed as the number of ﬁbres/
mm of epidermal length.
Analysis of spinal cord immunoreactivity was performed on
a minimum of ﬁve randomly selected L5 coronal spinal cord
sections from each of four animals per group (HIV-1 gp120
treated, RSA sham treated or naı¨ve) at 20· magniﬁcation.
The percentage area of ﬂuorescent-labelled ipsilateral and con-
tralateral GFAP or OX-42 staining in the dorsal horn (laminae
I–IV) was determined in a deﬁned area of 860 lm · 580 lm
using an automated grey-scale detection system and expressed
as means % ± SEM (Blackbeard et al., 2005). Analysis of the
ipsilateral and contralateral dorsal horns of biotin-labelled
spinal cord sections was performed at 20· magniﬁcation and
the activation state of the microglia assessed according to a
modiﬁed rating scale and guideline (Colburn et al., 1997),
where 0 represents the resting state, and 3 represents maximal
activation and displayed as the mean score (±SEM) over ﬁve
sections from each of four animals per group.
2.8. Statistical analysis
Sigmastat version 2.03 (SPSS Inc, Surrey, UK) was used to
determine the presence of statistically signiﬁcant diﬀerences
(P < 0.05) throughout the study. For behavioural reﬂex mea-
sures and open ﬁeld activity, all groups were compared using
a one-way analysis of variance (ANOVA) with Dunn’s all pair-
wise multiple comparisons post hoc analysis. For immunohis-
tochemical and pharmacological studies, experimental groups
were compared using a Kruskal–Wallis one-way ANOVA on
Ranks with an all pairwise multiple comparisons procedure
(Dunn’s Method). In all cases, the investigator was blinded
to the experimental status of each animal.
3. Results
3.1. Perineural HIV-1 gp120 causes mechanical but not
thermal or cold hypersensitivity
Similar to other well-characterised models of neuro-
pathic pain, rats exposed to perineural HIV-1 gp120
developed a long lasting, but reversible, mechanical
hypersensitivity of the ipsilateral hind paw as measured
by (a) calibrated graded von Frey ﬁlaments (gvF)
(Fig. 1A), and (b) the electronic von Frey device (evF)
(Fig. 1B) as compared to the contralateral hind paw or
Fig. 1. The development of reﬂex sensitivity to punctate mechanical stimuli, but not to thermal or cold stimuli, in the limb ipsilateral to perineural
HIV-1 gp120 treatment of the sciatic nerve. (A–D) Hind paw withdrawal thresholds to (A) graded von Frey ﬁlaments, (B) an electronic von Frey
device, (C) a noxious thermal stimulus and (D) an acetone drop, measured following perineural HIV-1 gp120 treatment of the sciatic nerve (n = 12)
or perineural RSA (sham) treatment of the sciatic nerve (n = 12). Statistical signiﬁcance of diﬀerences between paws ipsilateral (n) and contralateral
( ) to HIV-1 gp120 and ipsilateral to RSA (n) (*P < 0.05) was determined by a one-way ANOVA with Dunn’s all pairwise multiple comparisons or
(P < 0.05) between each value and the relevant baseline value (at time 0) using a one-way ANOVA with Dunnett’s multiple comparisons versus
control post hoc analysis. Each value is the mean ± SEM.
V.C.J. Wallace et al. / Pain 133 (2007) 47–63 51RSA (sham) treated rats. The heightened sensitivity to
both tests was signiﬁcant from day 9 after HIV-1 gp120
treatment, but reached peak values from day 12 until
day 21 post-surgery [average threshold between days 12
and 21: gvF = 15.3 ± 0.4 g (36% of BL) and
evF = 30.4 ± 1.0 g (56% of BL)]. The hypersensitivity
reversed to baseline values by day 52 post surgery. No
such hypersensitivity was apparent in the contralateral
hind paw or in sham animals. These tests also conﬁrmed
that the electronic von Frey device is a reliable and sensi-
tive test for the detection ofmechanical threshold changes
and therefore, we used only this apparatus for the remain-
der of mechanical reﬂex testing. In contrast to most nerve
injury induced models of neuropathic pain, there was no
evidence for the development of sensitivity to either ther-
mal (Fig. 1C) or cold stimuli (Fig. 1D). We observed no
overt motor deﬁcit following HIV-1 gp120 treatment
which was further conﬁrmed by measuring spontaneous
locomotor activity in the open ﬁeld area (see below).
3.2. HIV-1 gp120 treatment results in altered spontaneous
locomotor activity in the open ﬁeld arena
As a novel measure of pain related behaviour that
does not rely on reﬂex thresholds, we assessed the spon-
taneous exploratory activity of our rats in the open ﬁeld
activity paradigm which has been extensively employedfor the assessment of anxiolytic agents in rodents (Carli
et al., 1989; Holmes, 2001; Cryan and Holmes, 2005). As
an indicator of normal locomotion, there was no signif-
icant diﬀerence in the total distance moved by HIV-1
gp120 treated animals at day 7 or 14 post surgery versus
sham animals (Fig. 2A), suggesting a lack of overt
motor deﬁcit. However, at day 14 post surgery explora-
tion of the centre of the arena (as calculated by the num-
ber of entries into the inner zone and the time spent in
the inner zone) was signiﬁcantly decreased in HIV-1
gp120 treated animals as compared to shams or to either
treatment group at day 7(Fig. 2B–D). This lack of
exploration was associated with thigmotactic (‘wall-hug-
ging’ behaviour) (Fig. 2D).
3.3. HIV-1 gp120 associated mechanical hypersensitivity
is selectively responsive to clinically eﬀective analgesic
drugs
To assess the sensitivity of the perineural HIV-1
gp120 induced mechanical hypersensitivity to clinically
eﬃcacious analgesic compounds, we have evaluated
the analgesic eﬃcacy of amitriptyline, morphine, gaba-
pentin and the cannabinoid receptor agonist, WIN-
55,212-2, in our model. When administered between
days 15 and 18 post perineural HIV-1 gp120 adminis-
tration, amitriptyline (10 mg/kg i.p. b.d.) was not
Fig. 2. Spontaneous exploratory activity as measured in an open ﬁeld arena is altered in rats 14 days following perineural HIV-1 gp120 treatment of
the sciatic nerve. (A) The total distance moved within the open ﬁeld arena (1 m · 1 m) was assessed over 15 min and is not signiﬁcantly altered in
animals 7 and 14 days following perineural HIV-1 gp120 treatment as compared to perineural RSA (sham) treatment (n = 8 per group). (B) The
number of entries into the inner zone (40 · 40 cm) and (C) time spent in the inner zone of the open ﬁeld arena were signiﬁcantly reduced in rats 14
days following perineural HIV-1 gp120 treatment as compared to following perineural RSA (sham) treatment and to both treatment groups 7 days
post surgery. The statistical signiﬁcance of diﬀerences between all groups (*P < 0.05) was determined using a one-way ANOVA with Dunn’s all
pairwise multiple comparisons. Each value is the mean ± SEM. (D) Example traces of (i) sham versus (ii) HIV-1 gp120 treated rats over 15 min in the
open ﬁeld arena.
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ened sensitivity to punctuate mechanical stimuli as
compared to vehicle administration (Fig. 3A). In con-
trast, gabapentin (30 mg/kg, i.p. b.d. on days 15–18)
signiﬁcantly reversed the mechanical hypersensitivity
observed at day 14 (Fig. 3B) (d14 32.8 ± 1.9 g;
d18 = 48.1 ± 1.7 g). Vehicle administration had no sig-
niﬁcant eﬀect. Similarly, morphine (2.5 mg/kg i.p b.d.
on days 15–18) signiﬁcantly reversed the mechanical
hypersensitivity displayed at day 14 (Fig. 3C) (d14
37.0 ± 3.6 g; d18 = 43.1 ± 1.3 g). Finally, systemic
administration of the mixed CB1/CB2 cannabinoid
receptor agonist WIN 55,212-2 (2 mg/kg, i.p. b.d.) sig-
niﬁcantly reversed the mechanical hypersensitivity dis-
played at day 14 (Fig. 3D) (d14 36.5 ± 1.6 g;
d18 = 46.1 ± 2.3 g). The vehicle (40% DMSO) had a
small but signiﬁcant eﬀect on behaviour, however,
the analgesic eﬀect of WIN 55,212-2 was signiﬁcantly
greater indicating an eﬀect of the drug above the vehi-
cle. For all drugs tested, mechanical hypersensitivity
was re-established by day 28, indicating reversal of
the drug eﬀect and re-establishment of the neuropathic
state.3.4. LM and EM analysis reveals that overt axonal
damage is not a consequence of perineural HIV-1 gp120
treatment
To determine the extent of any damage to myelin-
ated axons in response to either the enwrapment pro-
tocol or speciﬁcally in response to perineural HIV-1
gp120 treatment, nerves were examined by light
microscopy prior to (day 7) and at the time of peak
behavioural change (day 14) in sham and treated ani-
mals. There was evidence of either primary demyelin-
ation or Wallerian degeneration at 7 days, and of
remyelination of aﬀected axons (as assessed by visual
examination) at 14 days, in both RSA (n = 6) and
HIV-1 gp120 (n = 8) treated nerves at the site of
application of the oxidised cellulose wrap. Aﬀected
axons tended to lie immediately deep to the perineu-
rium (Fig. 4A) in a pattern similar to that seen in
the ‘‘perineurial window’’ experimental model (Sugim-
oto et al., 2002): this suggests that at least some of the
changes were attributable to the enwrapment protocol
and that they occurred secondary to a disturbance of
perineurial integrity and/or of the microvascular bed
Fig. 3. Eﬀects of systemic administration of analgesic compounds on sensitised behavioural reﬂex responses following perineural HIV-1 gp120
treatment. Paw withdrawal thresholds in response to cutaneous punctate mechanical stimulation with an electronic von Frey device were measured in
animals following perineural HIV-1 gp120 to one sciatic nerve and the eﬀect of drugs delivered at the time of peak behavioural change assessed.
Ipsilateral values are displayed before, during and after i.p. administration of each pharmacological agent (n) versus the appropriate vehicle ( ) as
paw withdrawal threshold (g). Drug administration period (days 15-18) represented by shaded area. For all measurements, each value is the
mean ± SEM and statistical signiﬁcance (*P < 0.05) of any diﬀerences between drug and vehicle threshold values was determined by a Kruskal–
Wallis one-way ANOVA with Dunn’s all pairwise multiple comparisons group post hoc analyses. (A) Amitriptyline (10 mg/kg i.p. b.d.) (n = 8) had
no signiﬁcant eﬀect on behaviour versus the saline vehicle control (n = 8). (B) Gabapentin (30 mg/kg i.p. b.d.) (n = 8); (C) Morphine (2.5 mg/kg i.p.
b.d.) (n = 8); and (D) the mixed CB1/CB2 cannabinoid receptor agonist WIN 55,212-2 (2 mg/kg i.p. b.d.) (n = 8) all signiﬁcantly reversed
behavioural reﬂex sensitivity to mechanical stimulation versus the appropriate vehicle control (n = 8).
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in small outlying fascicles that had branched proxi-
mally from the parent sciatic nerve: these fascicles
commonly displayed clear evidence of discontinuities
of the perineurial cellular layers that were consistent
with a perineurial window eﬀect. Scattered degenerat-
ing axons were occasionally seen lying deeper within
the endoneurium in sham and treated animals; how-
ever the majority of axons appeared normal
(Fig. 4B). In marked contrast, the large nerve fascicles
appeared normal. Inspection at the EM level of the
day 14 tissue from sites just distal to, and at, the
application site conﬁrmed the LM ﬁndings in both
endoneurium and perineurium. Bundles of regenerat-
ing unmyelinated axons were seen within areas of
the endoneurium that contained remyelinating axons,
but there was no evidence of degeneration of unmyeli-
nated axons within endoneurium that appeared to be
‘‘morphologically normal’’ (Fig. 4C). Importantly,
there was no apparent diﬀerence to the extent and fre-
quency of signs of axonal damage between sham and
HIV-1 gp120 treated animals implying that this mini-
mal damage is associated with the surgical
preparation.3.5. Perineural HIV-1 gp120 is associated with decreased
intraepidermal nerve ﬁbre density
Immunostaining of skin biopsies for the neuronal
marker protein gene product 9.5 (PGP 9.5), a ubiqui-
tin carboxyl hydrolase (McCarthy et al., 1995; Ken-
nedy et al., 1996), can be used reliably and
reproducibly to quantify the intraepidermal nerve ﬁbre
(IENF) density (Smith et al., 2005) in humans and
rodents (McCarthy et al., 1995; Herrmann et al.,
1999; Lin et al., 2001; Keswani et al., 2006). Intraep-
idermal nerve ﬁbres, which represent the terminals of
C (nociceptive) ﬁbres, are known to degenerate in
patients with HIV-SN (Polydefkis et al., 2002). We
therefore employed such immunohistochemical meth-
ods to quantify IENF densities in the lateral plantar
surface of the hind paw of rats (i.e., the area inner-
vated by the sciatic nerve (Decosterd and Woolf,
2000)) treated with perineural HIV-1 gp120. At 14
days following perineural HIV-1 gp120, we found
there to be signiﬁcantly fewer nerve ﬁbres ipsilateral
to injury (22.5 ± 0.5/mm) as compared to sham trea-
ted (32.1 ± 0.8/mm) or contralateral foot skin
(29.7 ± 1.6/mm) (Fig. 5).
Fig. 4. Eﬀects of perineural treatment with RSA or HIV-1 gp120 on the integrity of axons in the sciatic nerve. (A–B) Toluidine blue-stained resin
sections (1 lm) from the site of application via an oxycellulose wrap of (i) RSA and (ii) HIV-1 gp120 to the sciatic nerve on day 14 post treatment. (A)
Examples of the sciatic nerve highlighting small areas of damage which occurred in the perineural window of the nerve. The broken line demarcates
the area of morphologically normal nerve from the damaged area. Scale bar = 20 lm. (B) Examples of nerve in which axons appear undisturbed. (C)
Examples of ultrathin sections of nerve within 1cm distal to the site of application of (i) RSA and (ii) HIV-1 gp120 to the sciatic nerve on day 14 post
treatment assessed by EM representing the majority of the nerve where myelinated and unmyelinated axons appear normal. Scale bar = 10 lm.
54 V.C.J. Wallace et al. / Pain 133 (2007) 47–633.6. Perineural HIV-1 gp120 is associated with increased
numbers of macrophages in the nerve
Macrophage inﬁltration and activation are cardinal
features of Wallerian degeneration in the PNS (Myers
et al., 1996; Abbadie et al., 2003). At days 3, 7 and 14
post application, we assessed the presence of macro-
phages in the HIV-1 gp120 treated sciatic nerve at the
site of application as well as 1 cm proximally and 1 cm
distally, using an antibody to CD68 (ED-1), a lysosomal
protein expressed by activated tissue macrophages. By
day 3, there was no evidence of activated macrophages
within the nerve. By day 7 there was a small but signif-
icant increase in the number of macrophages present in
and around the site of HIV-1 gp120 application as com-
pared to sham treated sciatic nerve (35.2 versus 2.5 pro-
ﬁles per 2 mm2) (Fig. 6A and B). At this time point, no
macrophages were detectable proximal or distal to the
application site or in the contralateral nerve. By day
14 the number of macrophages in the HIV-1 gp120 trea-
ted nerve had increased by more than 100% at the site of
application, whereas sham levels remained low (Fig. 6Aand C). Furthermore, at day 14, there was a signiﬁcant
spread of CD-68-IR macrophages into the proximal
region of the HIV-1 gp120 treated nerve which was
not apparent in the sham or in the distal portion of
the nerve in any treatment group (Fig. 6A). By day 45
post HIV-1 gp120 application, CD68-IR had returned
to basal levels (data not shown).
3.7. Perineural HIV-1 gp120 is associated with increased
ATF3, caspase-3 but not GAP-43 or c-Jun expression in
the DRG
By day 7, a small but signiﬁcant proportion of cells
(8.6%) in the DRG ipsilateral to perineural HIV-1
gp120 were immunoreactive for ATF3 as compared to
the contralateral DRG andDRG ipsilateral to perineural
RSA (Table 1). The majority of ATF3-IR neurons were
not co-localised with NF-200 indicating that they were
small diameter C-ﬁbre neurons. By day 14, 26.9% of
DRG neurons ipsilateral to perineural HIV-1 gp120 were
ATF3-IR compared to 4.6% ipsilateral to perineuralRSA
and 0.8% in the contralateral DRG (Table 1). Further-
Fig. 5. Intraepidermal nerve ﬁbre density is decreased following
perineural HIV-1 gp120. (A–C) Examples of PGP-9.5-immunoreactive
proﬁles (A) contralateral to HIV-1 gp120, (B) ipsilateral to RSA or (C)
ipsilateral to HIV-1 gp120 at day 14. (D) Immunohistochemical
analysis of the glabrous skin of the hind paw reveals decreased IENF
density ipsilateral to perineural HIV-1 gp120 by day 14 (n = 4) as
compared to hind paw contralateral to treatment (n = 4) or ipsilateral
to sham teatment (n = 4). Statistical signiﬁcance of diﬀerences between
groups (*P < 0.05) was determined by an ANOVA with Dunn’s all
pairwise multiple comparisons. Each value is the mean ± SEM. Scale
bar = 30 lm.
Fig. 6. The presence of macrophages in the HIV-1 gp120 treated
sciatic nerve. (A) Immunohistochemical analysis of the sciatic nerve
reveals the presence of immunoreactivity for the macrophage marker
CD68 at the site of administration of HIV-1 gp120 by day 7 (¤n = 6)
and day 14 (n n = 6) as well as a spread of macrophages into the distal
nerve by day 14 as compared to no signiﬁcant CD68-IR in the RSA
(sham) treated nerve at day 7 ( n = 6) or day 14 (h n = 6). Statistical
signiﬁcance of diﬀerences between groups (P < 0.05) was determined
by an ANOVA with Dunn’s all pairwise multiple comparisons where *
represents signiﬁcant diﬀerence from all other group and  represents
signiﬁcance from the appropriate sham control group. Each value is
the mean ± SEM. (B–C) Examples of CD68-immunoreactive proﬁles
at the site of (i) RSA or (ii) HIV-1 gp120 administration at (B) day 7
and (C) at day 14. Scale bar = 100 lm.
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ATF3 expressing neurons ipsilateral to HIV-1 gp120 at
day 14 were small diameter C-ﬁbre neurons (1252 of
1483 ATF3-IR cells were NF-200 negative) (Fig. 7A, a).
The increased expression of ATF3 at day 14 led us to
assess the DRG at day 14 for markers of apoptosis. We
investigated the presence of the pro-apoptotic proteins;
c-Jun and caspase-3 in the sensory neurons in the
DRG at times of peak behavioural sensitivity. Using a
phospho-speciﬁc antibody to detect the activated (phos-
phorylated) form of c-Jun (p-c-Jun) (Seijﬀers et al.,
2006) we found there to be no signiﬁcant upregulation
of the protein in DRG from HIV-1 gp120 treated ani-
mals as compared to sham animals (Fig. 7A, b and
Table 2). The small number of cells expressing this pro-
tein in both experimental groups is in line with previous
data indicating that activated c-Jun is present in some
naı¨ve non-injured neurons (Seijﬀers et al., 2006). How-
ever, there was a signiﬁcant expression of caspase-3 in
25.3% of cells ipsilateral to treatment as compared to
no signiﬁcant expression in contralateral DRG or in
sham DRG (Fig. 7A, c and Table 2). Similar to ATF3
expression in sections from the same DRG, the majority
of caspase-3 cells were small diameter C-ﬁbre neurons as
determined by NF-200 immunostaining.
Finally, in order to further assess consequences of
perineural HIV-1 gp120, we sought to assess whether a
regenerative process was present in nerves one week ortwo weeks following treatment. Consistent with the ﬁnd-
ings of previous studies (Caﬀerty et al., 2004), we
observe qualitatively three diﬀerent levels of GAP43-
IR. Under normal circumstances (i.e., in the absence
of injury), a large percentage of cells express low levels
of GAP43-IR (Van der Zee et al., 1989; Schreyer and
Skene, 1991) with a small percentage expressing elevated
GAP43-IR levels. Elevated expression levels are only
seen signiﬁcantly after a peripheral nerve injury in cells
associated with regenerating axons. Therefore, as a posi-
tive control we assessed expression levels of GAP-43-IR
in the ipsilateral DRG 7 days following partial sciatic
nerve injury of the sciatic nerve (Seltzer et al., 1990).
We used the results to set an automated detection level
for positive neurons following injury, and counted as
Table 1
ATF3 and GAP-43 immunoreactivity in DRG cells following perineural HIV-1 gp120 treatment
HIV-1 gp120 RSA sham
Ipsilateral Contralateral Ipsilateral
ATF3 day 7 8.6 ± 1.9%* (440 of 5126) 0.7 ± 0.6% (36 of 5231) 3.6 ± 1.9% (183 of 5110)
ATF3 day14 26.9 ± 2.9%* (1483 of 5502) 0.8 ± 0.6% (4 of 4960) 4.6 ± 2.4% (240 of 5236)
GAP43 day 7 2.6 ± 0.4% (91 of 3624) 2.7 ± 0.9% (111 of 4120) 2.6 ± 0.6% (113 of 4351)
GAP43 day 14 3.3 ± 1.8% (144 of 4977) 3.4 ± 0.7% (157 of 4624) 1.8 ± 0.6% (82 of 4922)
The expression of ATF3 and GAP-43 immunoreactivity as a percentage of total DRG cells ipsilateral and contralateral to HIV-1 gp120 treatment of
the sciatic nerve and ipsilateral to perineural RSA (sham) on post treatment day 14 (n = 6 in each case). Data are presented as means ± SEM. Total
cell counts are in brackets. There was a signiﬁcant increase in the expression of ATF3 at day 7 and day 14 post treatment in the DRG ipsilateral to
perineural HIV-1 gp120 as compared to contralateral and sham DRG (*P < 0.05) as determined by a Kruskal–Wallis one-way ANOVA on Ranks
with Dunn’s post hoc analysis. There was a small but signiﬁcant increase in ipsilateral sham DRG as compared to contralateral DRG (P < 0.05).
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similarly high levels of GAP-43 as an index of their
enhanced regenerative potential. At 7 and 14 days fol-
lowing perineural HIV-1 gp120 there was no signiﬁcant
increase in the percentage of GAP-43-IR neurons in the
DRG ipsilateral to HIV-1 gp120 treatment as compared
to contralateral DRG or DRG ipsilateral to sham treat-
ment (Table 1, Fig. 7A, d). This suggests that at times of
peak behavioural sensitivity, nerves treated with HIV-1
gp120 are not associated with a signiﬁcant axonal regen-
erative process. Furthermore, throughout all immuno-
histochemical analysis of the DRG, there was no
signiﬁcant diﬀerence in the total number of cells present
in six sections of DRG for each of six animals in HIV-1
gp120 treatment group (average of 4970.6 ± 310 cells)
versus sham (average of 4986.8 ± 140 cells) (see Tables
1 and 3 for counts), indicating a lack of overt neuronal
loss in the DRG.
3.8. The eﬀect of perineural HIV-1 gp120 on primary
sensory neuronal phenotype
To determine whether perineural HIV-1 gp120 is
associated with phenotypic changes in the DRG com-
mon to other models of nerve-injury induced pain, we
have examined the expression of the TRPV1 receptor
(Hudson et al., 2001) and the neuropeptides; CGRP,
galanin and NPY (Villar et al., 1991; Hokfelt et al.,
1994) at the time of peak behavioural change. By day
14, there was no overall change in the expression of
TRPV1 in neurons in the DRG ipsilateral to perineural
HIV-1 gp120 versus sham treatment or DRG contralat-
eral to perineural HIV-1 gp120 (Table 3, Fig. 7B, a).
Moreover, there was no signiﬁcant diﬀerence between
treatment groups in the percentage of small diameter,
NF200 negative cells that were TRPV1-IR
(gp120 = 52.5 ± 2.2% versus RSA = 57.8 ± 3.8%), indi-
cating that the lack of overall TRPV1-IR change was
not obfuscated by a change in the phenotype of
TRPV1-IR cells. Likewise, there was no signiﬁcant dif-
ference in the numbers of CGRP-IR neurons between
the DRG ipsilateral and contralateral to perineural
HIV-1 gp120 or as compared to sham treatment (Table3, Fig. 7B, b). In contrast, we observed signiﬁcant gala-
nin-IR in 13.9% neurons ipsilateral to perineural HIV-1
gp120 treatment as compared to 3.2% neurons ipsilat-
eral to RSA (sham) treatment and no signiﬁcant IR con-
tralateral to perineural HIV-1 gp120 (Table 3, Fig. 7B,
c). Of the galanin-IR cells 87% (513 of 590) did not
co-localise with NF200 suggesting the major population
of galanin expressing cells are small diameter C-ﬁbre
neurons. There was also signiﬁcant NPY-IR in approx-
imately 12.2% of DRG neurons as opposed to 1.6% ipsi-
lateral to RSA (sham) treatment and no detectable
immunoreactivity in contralateral DRG (Table 2). All
NPY-IR cells co-localised with NF-200-IR indicating
that they were cells with myelinated ﬁbres (Fig. 7B, d).
3.9. Alterations in non-neuronal cells in the DRG
following perineural HIV-1 gp120
To determine whether morphological changes occur
in satellite cells surrounding sensory neuronal cell bodies
in the DRG, we assessed the expression of GFAP, the
intermediate ﬁlament known to increase in expression
following peripheral nerve injury (Woodham et al.,
1989; Peters et al., 2005). Fourteen days following peri-
neural HIV-1 gp120, there was a signiﬁcant increase in
proportion of neurons associated with GFAP-IR satel-
lite cells in the DRG ipsilateral to perineural HIV-1
gp120 (11.6 ± 4.3%) as compared to DRG ipsilateral
to RSA (sham) treatment (3.6 ± 0.6%) and contralateral
DRG (1.6 ± 1.6%) (Fig. 7C, a).
Activated macrophages inﬁltrate injured peripheral
nerve tissue and therefore can be considered as universal
markers of PNS injury and are likely to be found follow-
ing most PNS lesion (Myers et al., 1996; Caterina et al.,
2000; Abbadie et al., 2003). Again using an antibody to
CD68 (ED-1), we assessed the presence of activated mac-
rophages in the DRG of perineural HIV-1 gp120 treated
animals.At 14days following treatment, therewas amod-
est but signiﬁcant increase in the average number of CD-
68-IR macrophages present per section of the DRG ipsi-
lateral to perineural HIV-1 gp120 (88.4 ± 7.4) as com-
pared to contralateral DRG (36.4 ± 8.6) and DRG
from sham treated animals (39.3 ± 4.7) (Fig. 7C, b).
Fig. 7. Immunohistochemical characterisation of the L5 DRG 14 days following perineural HIV-1 gp120. (A) Examples of the neuronal expression
of (a) ATF3 (green) co-stained for NF-200 (red); scale bar = 100 lm and (b) p-c-Jun (green) co-stained for ATF3 (red); scale bar = 30 lm (c)
caspase-3 and (d) GAP-43 with particular reference to high expressing cells; scale bar = 50 lm. (B) Examples of the neuronal expression of (a)
TRPV1 (green), (b) CGRP (green), (c) galanin (green) and (d) NPY (green), all co-stained for NF-200 (red) with co-localisation appearing in yellow;
scale bar = 100 lm. (C) Examples of the non-neuronal cell expression of (a) the satellite cell marker GFAP (green) and (b) the macrophage marker
CD68 (red); scale bar = 50 lm. Arrows indicate examples of cells immunoreactive for the protein of interest. All images are from the L4/L5 dorsal
root ganglia of animals exposed to (i) perineural RSA at day 14 versus (ii) perineural HIV-1 gp120. There was a statistically signiﬁcant increase in the
number of cells expressing ATF3, caspase-3, galanin, NPY, GFAP and CD68 in the DRG ipsilateral to perineural HIV-1 gp120 (n = 4–6) as
compared to DRG ipsilateral to perineural RSA (n = 4–6). No change was observed in p-c-Jun, GAP-43, TRPV1 or CGRP expression.
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In order to gain a better understanding of the central
consequences of peripherally applied HIV-1 gp120, as
well as to reproduce changes previously reported in a
similar model (Herzberg and Sagen, 2001), we assessedthe presence of morphological and population changes
in microglia and astrocytes in the dorsal horn of the
spinal cord, by measurement of OX-42-IR and GFAP-
IR, respectively. We examined two time points; day 7
following surgery, a time when behavioural changes
were minimal and day 14 following surgery, by which
Table 2
P-c-Jun and caspase-3 immunoreactivity in DRG cells following perineural HIV-1 gp120 treatment
HIV-1 gp120 RSA sham
Ipsilateral Contralateral Ipsilateral
p-c-Jun day 14 13.8 ± 0.7% (257 of 1965) 12.3 ± 2.6% (244 of 1975) 11.5 ± 0.8% (223 of 1998)
Caspase-3 day 14 25.3 ± 1.8%* (854 of 3420) 0% (0 of 3498) 0% (0 of 3268)
The expression of p-c-Jun and caspase-3 immunoreactivity as a percentage of total DRG cells ipsilateral to HIV-1 gp120 or RSA treatment of the
sciatic nerve post treatment day 14 (n = 4 in each case). Data are presented as means ± SEM. Total cell counts are in brackets. There was a signiﬁcant
increase in the expression of caspase-3 in the DRG ipsilateral to perineural HIV-1 gp120 as compared to sham DRG (*P < 0.05) as determined by a
Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s post hoc analysis.
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rating scale of 0–3 to assess the activation state of
microglia (adapted from (Colburn et al., 1997)), where
0 indicates the resting state and 3 represents a highly
activated state. At day 14, microglia in the dorsal horn
ipsilateral to perineural HIV-1 gp120 scored 2.1 ± 0.2
versus 0.9 ± 0.3 contralaterally, indicating that there
was a signiﬁcant qualitative, morphological change.
Such a change was not apparent at day 7 following per-
ineural gp120 or in sham treated animals (Fig. 8A and
B). We also assessed the density of microglia present
by measuring the percentage of a deﬁned area expressing
OX-42-IR (Blackbeard et al., 2005). At day 7 there was
a small but signiﬁcant increase in the density of microg-
lia in the ipsilateral dorsal horn as compared to sham
(Fig. 8A). Whereas, by day 14, there was a 5-fold
increase in the density of microglia in the dorsal horn
ipsilateral to perineural HIV-1 gp120 as compared to
sham values (Fig. 8A and C). There was no such change
contralateral to treatment. By day 14, HIV-1 gp120-
treated rats also exhibited a 5-fold increase in the density
of astrocytes present in the dorsal horn ipsilateral to
treatment versus the contralateral dorsal horn or versus
sham values (Fig. 8A and D). No such change was pres-
ent by day 7 following treatment.
4. Discussion
Over one-third of people living with HIV suﬀer pain-
ful peripheral neuropathies (Verma et al., 2005; Mar-Table 3
Immunohistochemical assessment of neuronally expressed proteins in DRG
HIV-1 gp120
Ipsilateral C
TRPV1 day 14 35.6 ± 1.9% (2347 of 6562) 3
CGRP day 14 28.4 ± 2.5% (1306 of 4694) 3
Galanin day 14 13.9 ± 1.3%* (590 of 4374) 0
NPY day 14 12.2 ± 1.9%* (838 of 4368) 0
The expression of TRPV1, CGRP, galanin and NPY immunoreactivity as a
gp120 treatment of the sciatic nerve and ipsilateral to perineural RSA (sham
means ± SEM. Total counts are in brackets. There was no signiﬁcant chang
increase in the expression of galanin and NPY in the DRG ipsilateral to p
(*P < 0.05) as determined by a Kruskal–Wallis one-way ANOVA on Ranks w
observed in ipsilateral sham DRG as compared to contralateral DRG (P <
CGRP or TRPV1 between groups as determined by a Kruskal–Wallis one-wshall et al., 2005), the mechanisms of which are poorly
understood. The HIV-1 coat protein, gp120, has been
linked to genesis of neuropathic pain (Oh et al., 2001;
Keswani et al., 2003; Melli et al., 2006). To ascertain
the biological capacity of gp120 to aﬀect the nerve
in vivo and so investigate the possible mechanisms
involved in the development of neuropathic changes,
we have pharmacologically and mechanistically charac-
terised a rodent model of HIV-1 gp120 induced neuro-
pathic pain.
HIV-1 gp120 induces mechanical hypersensitivity
with a time course that diﬀers in onset and duration to
other nerve-lesion pain models (Devor and Seltzer,
1999; Decosterd and Woolf, 2000). In further contrast
to many nerve-lesion models, but in line with clinical
data from patients with HIV-related painful neuropathy
(Martin et al., 2003), no hypersensitivity to heat or cold
stimuli developed. The hypersensitivity correlates with
decreased spontaneous exploratory behaviour and thig-
motaxis in the open ﬁeld, behaviour thought to correlate
to anxiety in rodents (Cryan and Holmes, 2005). This
suggests the presence of alterations in emotionally dri-
ven behaviour and may represent a pain-related co-mor-
bidity that can be utilised in the future.
To assess the suitability of this as a model in which to
study neuropathic pain mechanisms, we investigated the
eﬀects of known analgesic compounds. Amitriptyline
has known analgesic eﬃcacy in neuropathic pain in
experimental models (Abdi et al., 1998; De Vry et al.,
2004) and in the clinic (Hempenstall et al., 2005; Finn-cells 14 days following perineural HIV-1 gp120 treatment
RSA sham
ontralateral Ipsilateral
8.2 ± 2.6% (1962 of 5136) 32.8 ± 1.8% (1886 of 5624)
2.3 ± 2.6% (1453 of 4498) 33.4 ± 1.6% (1633 of 4842)
% (0 of 4672) 3.2 ± 1.5% (210 of 5308)
% (0 of 4310) 1.6 ± 0.3% (72 of 4502)
percentage of total DRG cells ipsilateral and contralateral to HIV-1
) on post treatment day 14 (n = 6 in each case). Data are presented as
e in TRPV1-IR or CGRP-IR between groups. There was a signiﬁcant
erineural HIV-1 gp120 as compared to contralateral and sham DRG
ith Dunn’s post hoc analysis. A small but signiﬁcant increase was also
0.05). There was no diﬀerence in the number of cells expressing either
ay ANOVA on Ranks.
Fig. 8. Immunohistochemical analysis of microglia and astrocytes in the dorsal horn of the L5 spinal cord 14 days following perineural HIV-1 gp120.
(i) There is a statistically signiﬁcant increase in the (A) morphological rating of microglia, (B) density of OX-42-IR and (C) density of GFAP-IR in L5
spinal cord dorsal horn ipsilateral versus contralateral to perineural HIV-1 gp120 at day 14 (n = 6) and compared to the dorsal horn ipsilateral to
perineural RSA (sham) at day 14 (n = 6) and ipsilateral to perineural HIV-1 gp120 or RSA at day 7 (n = 6). Statistical signiﬁcance of diﬀerences
between groups (P < 0.05) was determined by an ANOVA with Dunn’s all pairwise multiple comparisons where * represents signiﬁcant diﬀerence
from all other groups. Each value is means ± SEM. (ii and iii) Examples of the expression of (A) OX-42-IR with biotin labelling for qualitative
analysis in the L5 spinal cord dorsal horn, (B) OX-42-IR with ﬂuorescence labelling for quantitative analysis in the dorsal horn of the L5 spinal cord,
and (C) GFAP-IR with ﬂuorescence labelling in the L5 spinal cord dorsal horn at day 14 (ii) ipsilateral to perineural RSA and (iii) ipsilateral to
perineural HIV-1 gp120. Scale bar = 50 lm.
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that amitriptyline is not eﬀective for the treatment of
HIV related neuropathic pain (Kieburtz et al., 1998;
Shlay et al., 1998), and amitriptyline had no eﬀect on
mechanical hypersensitivity in our model. In contrast,
gabapentin and morphine were both eﬀective in our
model. Gabapentin is analgesic in rodent (Abdi et al.,
1998; De Vry et al., 2004; Donovan-Rodriguez et al.,
2005) and human neuropathic pain conditions (Hem-
penstall et al., 2005; Finnerup et al., 2005), including
HIV-neuropathy (Hahn et al., 2004). Morphine attenu-
ates hypersensitivity in rodent neuropathy models (Lee
et al., 1994; Backonja et al., 1995) and evidence is accu-
mulating to suggest that opioids relieve symptoms of
human neuropathic pain of peripheral origin (Hempen-
stall et al., 2005; Finnerup et al., 2005). The eﬀects of
these analgesics in our model correlate well with their
clinical eﬃcacy further supporting the use of this model
for the assessment of novel therapeutic agents. For
example, evidence indicates that cannabinoids may exertbeneﬁcial eﬀects including analgesia in human neuro-
pathic pain (Rice, 2005; Finnerup et al., 2005). Here
we have shown that in line with previous rodent neuro-
pathic pain studies (Bridges et al., 2001; Farquhar-Smith
et al., 2002; Wallace et al., 2003), the CB1/CB2 receptor
agonist, WIN 55,212-2, eﬀectively attenuated HIV-1
gp120 induced mechanical hypersensitivity further sup-
porting the potential therapeutic beneﬁt of
cannabinoids.
To understand mechanisms of HIV-1 gp120 related
neuropathic behaviour, we sought to establish whether
axonal damage is a consequence of gp120 application.
LM and EM investigations revealed relatively few
demyelinating and degenerating large diameter axons
and little evidence for damage to unmyelinated axons
at sites distal to or at the application site. Additionally,
the lack of increased expression of the axonal regener-
ation marker GAP-43 (Schreyer and Skene, 1991), as
well as a lack of macrophages in the distal nerve, indi-
cate that widespread axonal damage and regeneration,
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consequence of this model. The absence of axonal
degeneration in the peripheral nerve does not rule
out the possibility of a degenerative process in the sen-
sory neuron peripheral terminal arbors, which has been
shown to be a feature of alternative models of neurop-
athy (Siau et al., 2006). Quantiﬁcation of intraepider-
mal nerve ﬁbre density in the plantar hind paw
revealed gp120 treated nerves to have reduced numbers
of C-ﬁbre peripheral terminals at times of peak behav-
ioural sensitivity. IENF density is commonly used for
diagnosis of sensory neuropathy (McCarthy et al.,
1995; Kennedy et al., 1996; Lin et al., 2001) and is
inversely correlated with the presence of neuropathic
pain in HIV patients (Polydefkis et al., 2002). Further-
more, the cell stress marker, ATF3 (Tsujino et al.,
2000), was signiﬁcantly expressed at this time particu-
larly in small diameter sensory neurons. These results
reﬂect the clinical scenario in which HIV-DSP is
thought to be a predominantly small ﬁbre neuropathy
aﬀecting the distal nerve (Martin et al., 2003; Verma
et al., 2005) and are in line with recent in vitro evidence
(Melli et al., 2006) supporting neurotoxicity of gp120
on axons. This may represent a mechanism by which
HIV infection results in axonopathy in humans and
further supports the use of this model in the investiga-
tion of such mechanisms.
The presence of macrophage inﬁltrates within the
peripheral nerve and DRG of HIV/AIDS patients, with
concomitant presence of pro-inﬂammatory cytokines
(de la Monte et al., 1988; Yoshioka et al., 1994; Nagano
et al., 1996; Pardo et al., 2001), links HIV-1 infection
with an inﬂammatory response within the nerve and
DRG. Correlating with the clinical scenario, signiﬁcant
numbers of macrophages are present in the gp120 trea-
ted nerve in a time course consistent with hypersensitiv-
ity. Macrophage derived inﬂammatory mediators likely
inﬂuence nerve function and associated sensory abnor-
malities observed in this model and may therefore
emerge as useful therapeutic targets.
Primary sensory neuron gene expression changes are
known consequences of nerve injury and may contribute
to peripheral and central plasticity (Costigan et al.,
2002). At the time of peak behavioural change we found
no change in DRG expression of CGRP or TRPV1.
Dysregulation of both proteins following peripheral
nerve injury (Villar et al., 1991; Hudson et al., 2001)
has been suggested to correlate with the development
of thermal hyperalgesia (Caterina et al., 2000; Mogil
et al., 2005), a phenomenon that is neither a feature of
our model, nor of clinical data (Martin et al., 2003).
However, the expression of galanin, NPY; the satellite
cell marker, GFAP and the macrophage marker,
CD68, did increase in the DRG, all of which are features
of models of nerve-lesion associated pain (Ma and Bis-
by, 1998; Wynick et al., 2001). Although of a smallermagnitude than seen in nerve lesion models, these
changes suggest that HIV-1 gp120 in the nerve can pro-
duce changes usually associated with actual nerve
trauma and may further reﬂect gp120 induced axonal
injury.
A number of studies have linked gp120 to induc-
tion of apoptosis in neurons (Lipton, 1991; Keswani
et al., 2003; Melli et al., 2006). The pro-apoptotic pro-
teins c-Jun (Ham et al., 2000) or caspase-3 (Beattie
et al., 2002) elicit apoptosis in various cells, and can
increase following nerve injury (De Felipe and Hunt,
1994; Kenney and Kocsis, 1998; Jiang et al., 2005)
or exposure to gp120 in vitro (Singh et al., 2005).
We found that caspase-3, but not p-c-Jun, increased
in the DRG suggesting that speciﬁc apoptotic path-
ways are induced by HIV-1 gp120. The expression
of caspase-3, particularly in small diameter neurons,
implies that these cells may undergo apoptosis with
the resultant loss of small calibre axons at later time
points. As mentioned above, HIV-DSP presents as a
small ﬁbre neuropathy and such mechanisms may well
contribute and therefore merit further investigation.
Furthermore, these data correlate well with in vitro
studies which link gp120 induced apoptosis to cas-
pase-3 dependent mechanisms (Keswani et al., 2003;
Melli et al., 2006) and indicate that this model lends
itself to the investigation of the biological eﬀect of
gp120 on peripheral axons. Therefore, although not
a direct model of HIV-associated neuropathy in
man, the current model will likely prove useful in
future studies to unravel mechanisms of gp120 related
neuropathic events.
Finally, we have demonstrated spinal gliosis in a time
course consistent with pain-like behaviour. Spinal astro-
cytes and microglia can produce and/or respond to a
number of pronociceptive substances (Tsuda et al.,
2005) and their activation has been demonstrated in var-
ious models of neuropathic pain (Colburn et al., 1997;
Milligan et al., 2003; Tanga et al., 2004). This suggests
a mechanism by which HIV-1 gp120 can induce long-
lasting central neuropathology in the absence of direct
CNS infection and may point towards potential thera-
peutic agents (Tsuda et al., 2005).
These ﬁndings lead to important questions as to the
mechanisms by which HIV-1 gp120 induces neuropathic
changes and pain. HIV-1 gp120 binds to the chemokine
receptors CXCR4 and CCR5, the natural ligands of
which (SDF-1a and RANTES) can induce behavioural
correlates of pain in rats (Oh et al., 2001). Both recep-
tors are expressed on rat DRG neurons (Oh et al.,
2001), axons (Melli et al., 2006) and by macrophages
(Lee et al., 2003). We have demonstrated the presence
of macrophages in the HIV-1 gp120 treated nerve as well
as correlates of axonal injury at peripheral terminals and
in the DRG implying that these receptors are feasible
sites of action in this model. However, this mechanism
V.C.J. Wallace et al. / Pain 133 (2007) 47–63 61of HIV-1 gp120 induced neuropathic changes has yet to
be proven and this study suggests that this model would
lend itself to such investigation.
In conclusion, we have characterised a neuropathic
pain model that mimics many features of HIV-DSP.
The associated characteristics, especially the robust but
speciﬁc behavioural changes, highlight the utility of this
model for many further mechanistic studies and poten-
tially the discovery of new therapeutic targets for the
treatment of neuropathic pain.Acknowledgements
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